Fannie Mae, Freddie Mac shares tumble after conservatorship comments
BLOOMFIELD - The Cigna Group (NYSE:CI), a global health service company with a market capitalization of $84 billion and "GREAT" financial health according to InvestingPro analysis, announced today that Michael J. Hennigan has joined its Board of Directors. Hennigan currently serves as the Executive Chairman of Marathon Petroleum Corporation (NYSE:MPC) and MPLX, a master limited partnership formed by Marathon Petroleum.
With a career spanning over three decades in the energy sector, Hennigan brings a wealth of experience in refining, logistics, and marketing. His previous roles include CEO of Marathon Petroleum and Chairman, President, and CEO of MPLX. He also served as President at Energy Transfer Partners L.P. and held various leadership positions at Sunoco, Inc. He joins Cigna during a period of strong performance, with the company generating over $255 billion in revenue over the last twelve months.
David Cordani, President and CEO of The Cigna Group, expressed confidence in Hennigan’s abilities, citing his "extensive business experience and proven track record in leading significant strategic initiatives." Cordani highlighted Hennigan’s deep understanding of regulated markets and his commitment to operational excellence as assets that will contribute to Cigna’s growth and the enhancement of customer healthcare experiences.
Hennigan’s appointment is part of Cigna’s ongoing efforts to strengthen its leadership team and drive its mission forward. The company, which operates globally and has over 190 million customer relationships, is known for its health services marketed under various brands, including Cigna Healthcare and Evernorth Health Services.
The information in this article is based on a press release statement from The Cigna Group. According to InvestingPro analysis, Cigna appears undervalued based on its Fair Value calculations, with 12+ additional exclusive insights available to subscribers. The company has maintained dividend payments for 44 consecutive years, demonstrating long-term financial stability.
In other recent news, Cigna Corporation reported its first-quarter 2025 earnings, exceeding Wall Street expectations with an adjusted earnings per share (EPS) of $6.74 and revenue of $65.5 billion, surpassing forecasts of $6.35 EPS and $60.38 billion in revenue. The company has raised its full-year 2025 EPS guidance to at least $29.60, attributing this increase to the delayed sale of its Medicare Advantage business, which positively impacted earnings. UBS analyst AJ Rice reiterated a Buy rating for Cigna, highlighting the company’s strategic exit from Medicare Advantage as a positive move and expressing confidence in Cigna’s ability to achieve low-double-digit earnings growth over time. Meanwhile, Bernstein raised its price target for Cigna to $373 while maintaining a Market Perform rating, acknowledging Cigna’s strong performance but expressing concerns about its growth potential without Medicare or Medicaid exposure. Raymond James also lifted its price target to $385, maintaining a Strong Buy rating, citing the company’s better-than-expected first-quarter results. Jefferies increased its price target to $397, maintaining a Buy rating, and emphasized Cigna’s strong performance, particularly in its Specialty segment. These developments reflect a positive outlook among analysts, with expectations of continued stability and growth for Cigna.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.